A Study on the Latest Results of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer Utilising PD-1 Monoclonal Antibody in Combination with Platinum Antineoplastic Agent and Tegafur Chemotherapy

Advances in Clinical Medicine Pub Date : 2023-01-01 DOI:10.12677/acm.2023.13112448

浣茹梁

{"title":"A Study on the Latest Results of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer Utilising PD-1 Monoclonal Antibody in Combination with Platinum Antineoplastic Agent and Tegafur Chemotherapy","authors":"浣茹梁","doi":"10.12677/acm.2023.13112448","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the efficacy and safety of programmed cell death receptor1 (PD-1) monoclonal antibody combined with platinum antineoplastic agent + tegafur for neoadjuvant chemotherapy of locally advanced gastric cancer. Methods: Clinical data of 53 patients with locally advanced gastric cancer adenocarcinoma (cT3-4aNxM0) who received preoperative neoadjuvant chemotherapy from 2018 to March 2023 at the Second Affiliated Hospital of Anhui Medical University were retrospectively analyzed. Based on whether PD-1 was used or not, they were divided into the control group and the observation group. The control group (n = 28) was treated with platinum (oxaliplatin/lobaplatin/cisplatin) + tegafur regimen, and the observation group (n = 25) was treated with the addition of a PD-1 inhibitor (Carelizumab in 12 cases/Sintilimab in 13 cases) on top of the control group. All of them were treated with 3 cycles of preoperative chemotherapy. The clinical efficacy and adverse reactions of the two groups were compared. The clinical characteristics of patients who underwent D2 standard radical surgery were compared: R0 resection rate, tumor regression grade, major pathologic response (MPR) rate, etc. The risk factors affecting MPR were then explored by univariate and multivariate regression analysis. Results: The","PeriodicalId":7237,"journal":{"name":"Advances in Clinical Medicine","volume":"77 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Clinical Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12677/acm.2023.13112448","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the efficacy and safety of programmed cell death receptor1 (PD-1) monoclonal antibody combined with platinum antineoplastic agent + tegafur for neoadjuvant chemotherapy of locally advanced gastric cancer. Methods: Clinical data of 53 patients with locally advanced gastric cancer adenocarcinoma (cT3-4aNxM0) who received preoperative neoadjuvant chemotherapy from 2018 to March 2023 at the Second Affiliated Hospital of Anhui Medical University were retrospectively analyzed. Based on whether PD-1 was used or not, they were divided into the control group and the observation group. The control group (n = 28) was treated with platinum (oxaliplatin/lobaplatin/cisplatin) + tegafur regimen, and the observation group (n = 25) was treated with the addition of a PD-1 inhibitor (Carelizumab in 12 cases/Sintilimab in 13 cases) on top of the control group. All of them were treated with 3 cycles of preoperative chemotherapy. The clinical efficacy and adverse reactions of the two groups were compared. The clinical characteristics of patients who underwent D2 standard radical surgery were compared: R0 resection rate, tumor regression grade, major pathologic response (MPR) rate, etc. The risk factors affecting MPR were then explored by univariate and multivariate regression analysis. Results: The

查看原文